MDMA clinical trials in the registry
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
MDMA (3,4-methylenedioxymethamphetamine) is a synthetic compound that registered studies often pair with structured psychological support. This page summarises registered studies whose registry records mention MDMA, using PsychoactiveMap's copy of the ClinicalTrials.gov registry.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 109 registered MDMA studies are counted on this page.
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 21 | 19% |
| Not yet recruiting | 5 | 5% |
| Enrolling by invitation | 2 | 2% |
| Active, not recruiting | 3 | 3% |
| Completed | 62 | 57% |
| Terminated | 4 | 4% |
| Withdrawn | 6 | 6% |
| Status not reported | 6 | 6% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 8 | 7% |
| Phase 1 | 35 | 32% |
| Phase 2 | 42 | 39% |
| Phase 3 | 7 | 6% |
| Not applicable | 10 | 9% |
| Not reported | 7 | 6% |
Countries
Country is taken from the study's linked research site. 1 of 109 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 65 | 60% |
| Switzerland | 25 | 23% |
| Israel | 5 | 5% |
| Canada | 4 | 4% |
| Spain | 3 | 3% |
| Netherlands | 2 | 2% |
| Australia | 1 | 1% |
| Czechia | 1 | 1% |
| France | 1 | 1% |
| United Kingdom | 1 | 1% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 36 |
| 2020 to 2023 | 31 |
| 2015 to 2019 | 10 |
| 2010 to 2014 | 20 |
| Before 2010 | 11 |
| Start date not reported | 1 |
Study design
- 102 interventional and 6 observational studies.
- Median planned or actual enrolment is 24 participants (range 2 to 1,500, across 102 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Trauma and PTSD | 48 |
| Other substance use | 18 |
| Healthy volunteers | 12 |
| Anxiety | 4 |
| Alcohol use | 3 |
| Cancer and end of life | 2 |
| Pain and headache | 1 |
| Eating disorders | 1 |
Most recently started studies
The 25 studies with the latest start dates, shown newest first. The order is not a ranking and says nothing about quality. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07765693 | MDMA-AT for PTSD in Young Adults With Childhood Trauma | Not yet recruiting | Phase 2 | United States | 2026-10 |
| NCT07704762 | Clinical Trial of MDMA-Assisted Therapy for Military Service Members With Posttraumatic Stress Disorder | Not yet recruiting | Phase 2 | Not reported | 2026-10 |
| NCT07555132 | Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls | Not yet recruiting | Not applicable | Switzerland | 2026-06 |
| NCT07542145 | MDMA Assisted Therapy for BN | Recruiting | Phase 1 | United States | 2026-05 |
| NCT07569159 | MDMA Therapy in Veterans With PTSD | Recruiting | Phase 2 | United States | 2026-05 |
| NCT07584720 | Study of Midomafetamine in Healthy Adults | Active, not recruiting | Phase 1 | United States | 2026-04 |
| NCT07118839 | MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder | Recruiting | Phase 2 | United States | 2026-04 |
| NCT05455996 | MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers | Not yet recruiting | Phase 2 | United States | 2026-04 |
| NCT06066853 | MDMA-assisted Therapy for Fibromyalgia | Recruiting | Early Phase 1 | United States | 2026-04 |
| NCT03606538 | MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function | Not yet recruiting | Phase 1 | United States | 2026-03 |
| NCT07494214 | Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants | Recruiting | Phase 1 | Switzerland | 2026-03 |
| NCT04454684 | A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders | Withdrawn | Phase 2 | United States | 2026-02 |
| NCT07102576 | MDMA-Assisted Therapy for Mental Healthcare Providers | Recruiting | Phase 1 | United States | 2026-01 |
| NCT07288151 | MDMA-Assisted Massed Exposure Therapy for PTSD | Recruiting | Phase 2 | United States | 2026-01 |
| NCT07469098 | Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events | Recruiting | Phase 2 | Israel | 2025-12 |
| NCT06989957 | Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) | Recruiting | Phase 1 | United States | 2025-09 |
| NCT05783817 | MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) | Recruiting | Phase 2 | United States | 2025-09 |
| NCT06683014 | MDMA in Borderline Personality Disorder | Recruiting | Phase 2 | United States | 2025-09 |
| NCT06905652 | Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants | Completed | Phase 1 | Switzerland | 2025-07 |
| NCT06353282 | MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents | Withdrawn | Phase 2 | United States | 2025-07 |
| NCT06418178 | Dose Optimization of MDMA-Assisted Therapy for PTSD | Recruiting | Phase 2 | United States | 2025-06 |
| NCT06954025 | High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD | Enrolling by invitation | Phase 2 | Netherlands | 2025-05 |
| NCT06884514 | Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects | Completed | Phase 1 | Switzerland | 2025-04 |
| NCT05770375 | Tolerability of MDMA in Schizophrenia | Recruiting | Phase 1 | United States | 2025-04 |
| NCT05790239 | MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder | Recruiting | Phase 2 | United States | 2025-03 |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals.
Other substance hubs
Psilocybin | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable